Extrahepatic bile duct carcinoma is one of the most extremely aggressive cancers with poor prognosis after curative resection. Syndecan-1 and E-cadherin are transmembrane glycoproteins, and have important roles in cell-cell adhesion and tumor progression. In this study, we examined 84 surgically resected cases of extrahepatic bile duct adenocarcinoma to clarify clinicopathological significance of syndecan-1/E-cadherin expression. Reduced expressions of syndecan-1 and Ecadherin were found in 69.0% (58/84) and 46.4% (39/84) of the bile duct carcinomas. Reduced syndecan-1 expression was correlated with lymphatic/venous/nervous invasion (P < 0.0001), and was associated with short overall survival (P = 0.0002). Reduced E-cadherin expression was correlated with lymphatic and nervous invasion (P = 0.008, P < 0.0001, respectively), and was associated with short overall survival (P = 0.0038). The results indicated that reduced syndecan-1/ E-cadherin expression may be good indicators of recurrence and prognosis in extrahepatic bile duct carcinoma.
Extrahepatic bile duct carcinoma is a malignancy arising from the epithelial cells of the bile duct. It occurs with a greater frequency in Asian countries, and is one of the common causes of cancer death in Japan, with near to 17,000 deaths annually (20) . Most of the patients present jaundice because the carcinoma invasion results in stenosis of the extrahepatic bile duct. This tumor has been generally considered as one of the most extremely aggressive cancers with poor prognosis even after curative resection (24, 37, 47) . Syndecans are a family of transmembrane heparan sulfate proteoglycans, and have important roles in a variety of cellular functions, including cell proliferation and cell-matrix and cell-cell adhesion (7, 8, 54) . In vertebrates the syndecan family comprises four members. Syndecan-1 is the major syndecan in epithelial cells, syndecan-2 predominates in fibroblasts, syndecan-3 abounds in neural cells, and syndecan-4 is widely expressed. The most dramatic changes in syndecan expression occur during development and are associated with morphological transitions, cell differentiation, or changes in tissue organization. Syndecan-1 expression is also modified in pathological situations, such as wound healing and neoplastic transformation (7, 8, 12, 30, 54) . E-cadherin is a member of the tarnsmembrane glycoprotein family and is responsible for the epithelial cell-cell adhesion molecule expressed by epithelial cells (29, 44, 52) . Reduction and loss of the E-cadherin expression in cancer cells may show the destruction of the junctional structure which can affect the intercellular adhesion, and promote tumor progression and metastasis. The expression is related to survival and prognosis in a portion of cancers, such as colorectal, esophageal and pancreatic cancers (19, 21, 53) . In this study, we performed expression of synde-pancreaticoduodenectomy was performed in 50 patients, bile duct resection in 21 patients, hepatectomy with bile duct resection in 12 patients, and combined hepatectomy and pancreaticoduodenectomy in one patient. The pathological stage of each case at the time of operation was defined according to the TNM classification, and classification of biliary tract carcinoma (16, 26) . The present study followed the principles of the World Medical Association Declaration of Helsinki 1964.
Immunohistochemistry. For histological examination, extrahepatic bile duct carcinoma specimens were routinely fixed with formalin, embedded in paraffin, thin-sectioned, and stained with hematoxylin and eosin. In each case, one representative histological specimen at the deepest invaded area of bile duct cancer lesion was selected for immunohistochemistry. Four-μm-thick sections were mounted on silane-coated glass slides. Immunohistochemical examination was performed on deparaffinized sections using the standard avidin-biotin-peroxidase complex method with automated immunostainer (Benchmark can-1 and E-cadherin in 84 extrahepatic bile duct carcinomas in order to elucidate whether the syndecan-1 and E-cadherin expression is correlated with clinicopathological features and clinical outcomes.
MATERIALS AND METHODS
Patient's materials. We analyzed surgically resected tissues of 84 patients with carcinoma arising from the extrahepatic bile ducts, after obtaining each patient's informed consent to use their clinical records and pathology specimens field in Hirosaki University Hospital. Survival data were obtained from hospital medical charts and by contacting patients or their family, and median observation period was 41 months. The series consisted of 57 men and 27 women with median age of 66 years (range, 27-83 years). The carcinomas were located to the hilar (26 cases), middle (29 cases), or distal bile duct (29 cases), according to anatomic location (24, 26, 47) . Curative resection and regional lymph node dissection depended on the location of the primary tumors. Pancreaticoduodenectomy or pylorus-preserving ing in tumor cells; preserved, ≥ 30% of staining in tumor cells. Immunohistochemical expression of E-cadherin was classified into the following two groups: reduced, < 50% of staining in tumor cells; preserved, ≥ 50% of staining in tumor cells.
Statistical analysis. Univariate statistical analysis was performed using the Pearson chi-square test or Fisher exact test. Survival curves were constructed using the Kaplan-Meier method and differences in survival were evaluated using log-rank test. The relative prognostic factors were analyzed with the Cox's proportional hazards regression model. All statistical evaluations were performed using the XT; Ventana Medical System, Tucson, AZ, USA). First antibodies of immunohistochemistry were anti-human syndecan-1 (anti-human CD138, clone MI15, mouse monoclonal, 1 : 50 dilution; Dakocytomation, Denmark) and anti-human E-cadherin (clone 4A2C7, mouse monoclonal, 1 : 100 dilution; Zymed laboratories Inc., South San Francisco, CA, USA). Heat-induced antigen retrieval was performed for each antigen.
Evaluation of immunohistochemistry.
Immunohistochemical expression of syndecan-1 was evaluated in invasive region of tumors, and was classified into the following two groups: reduced, < 30% of stain- also correlated with lymphatic and nervous invasion (P = 0.008, P < 0.0001, respectively). In addition, reduced expressions of syndecan-1 and E-cadherin were significantly associated with recurrent status (P < 0.0001, P = 0.013, respectively), while the expression was not associated with lymph node metastasis.
Survival curves based on the univariate survival analysis demonstrated that the preserved syndecan-1 expression was associated with favorable overall survival (P = 0.0002, Fig. 2A) , and disease free survival (P = 0.0002, Fig. 2B ). The preserved E-cadherin expression was associated with favorable overall survival (P = 0.0038, Fig. 3A ) and disease free survival (P = 0.018, Fig. 3B ). In addition to the syndecan-1/E-cadherin, patient's survival was significantly associated with the histological grade, depth of tumor invasion, lymph node metastasis, lymphatic invasion, venous invasion, and nervous invasion ( Table 2) .
Results of multivariate analysis for overall survival and disease free survival were summarized in Ta-SPSS software (version 11.0; SPSS, Inc., Chicago, IL, USA).
RESULTS
Typical immunohistochemical expression of syndecan-1 and E-cadherin was demonstrated in Fig. 1 . Preserved syndecan-1 expression was found at the membrane and/or in the cytoplasm of tumor cells. Reduced syndecan-1 expression was detected at the basal membrane of several tumor cells. Preserved E-cadherin expression was diffusely found at the membrane of tumor cells. Reduced E-cadherin expression was detected at the basolateral membrane of several tumors. Relationships between syndecan-1/E-cadherin expression and clinicopathological factors were summarized in Table 1 . Syndecan-1 and E-cadherin expressions were correlated with depth of tumor invasion (P = 0.005, P = 0.025, respectively). Lymphatic/venous/nervous invasion was significantly correlated with reduced syndecan-1 expression (P < 0.0001). E-cadherin expression was ble 3. Syndecan-1 expression and nervous invasion had independent prognostic value influencing both overall survival and disease free survival. Lymph node metastasis had independent prognostic value influencing only overall survival. However, E-cadherin expression was not independent.
DISCUSSION
Syndecan and cadherin are transmembrane glycoproteins, and play important roles in a variety of cellular functions, including cell-cell adhesion. However, expression and function of the syndecan/cadherin have not yet been clarified in the extrahepatic bile duct carcinoma extensively. In this study, we demonstrated that reduced expression of syndecan-1 and E-cadherin was correlated with the recurrent status of bile duct carcinoma, as well as the short overall survival. This is the first study to elucidate relationships between the syndecan-1/E-cadherin expression and clinical outcomes of extrahepatic bile duct carcinomas. Extrahepatic bile duct carcinoma is a malignancy arising from the epithelial cells of the extrahepatic 41). Enhanced syndecan-1 expression has been observed in pancreatic (11, 27) , breast (4, 33) , and prostate cancers (9, 48) . In the studies of hepatobiliary region, decreased syndecan-1 was correlated with distant metastasis and high histological grade of hepatocellular carcinoma (35, 38) , and was associated with high histological grade, lymph node metastasis, and poor prognosis of intrahepatic cholangiocarcinoma (17) . We elucidated that reduction of syndecan-1 expression in extrahepatic bile duct carcinomas was significantly correlated with high tumor grade, vascular/nervous invasion, and short patient's survival in both of univariate and multivariate analysis. On the other hand, alterations of E-cadherin expression have been reported in human tumors. In cholangiocarcinoma, E-cadherin expression was reduced in aggressive histological types (3, 40) . We elucidated here that reduction of E-cadherin expression in extrahepatic bile duct carcinomas was significantly correlated with high tumor grade, vascular/nervous invasion, and short patient's survival. Two experimental studies suggested a coordinate regulation of syndecan-1 and E-cadherin expression (34, 51) . In recent studies, synchronous reduction of syndecan-1 and E-cadherin expression associated with carcinogenesis or prognosis has been reported in skin, stomach, colon, and thyroid cancers (4, 10, 13, 41) . In the present study, synchronous reduction of syndecan-1 and E-cadherin expression was observed in extrahepatic bile duct carcinoma.
In conclusion, reduced syndecan-1 and E-cadherin bile duct. Previous studies have reported that patient's prognosis of the extrahepatic bile duct carcinoma was associated with several clinicopathological features, such as tumor histological type, lymph nodal status, stage, location, vascular/nervous invasion and surgical margin (14, 31, 43, 46) . Our study also demonstrated that the histological grade, lymph nodal status, and vascular/nervous invasion were significantly associated with clinical outcome. Especially, nervous invasion was shown to have independent prognostic value in multivariate analysis. Despite of recent advances in surgical management of the bile duct carcinoma, there have not been favorable survival data (24, 37, 47) . Therefore, further studies and clinical applications of the prognostic factors are still necessary in the oncology field of extrahepatic bile duct. Syndecan-1 and E-cadherin have important roles not only in cell-cell adhesion, but also in tumor progression. In experimental studies of malignant transformation, syndecan-1 expression is associated with the maintenance of epithelial morphology, anchorage-dependent growth, and inhibition of invasiveness (6, 7, 8, 12, 28, 54) . Previous studies have reported that downregulation of syndecan-1 was correlated with high histological grade, advanced stage, and poor prognosis in several common tumors, such as uterine cervix (23, 49) , oral epithelium (32, 50) , head and neck (2, 22) , larynx (45) , esophagus (39) , lung (1, 42) , skin (5), endometrium (18) , stomach (10), colon (13, 15) , breast (36) , and thyroid (25, expressions were correlated with poor patient's prognosis and recurrent status. In multivariate analysis, syndecan-1 expression had independent prognostic value influencing clinical outcome. Therefore, syndecan-1 expression is thought to become a novel predictor of recurrence and prognosis of the extrahepatic bile duct carcinoma.
